This is a preview of subscription content, log in via an institution to check access.
REFERENCES
J. P. Skelly, G. A. Van Buskirk, D. R. Savello, G. L. Amidon, H. M. Arbit, S. Dighe, M. B. Fawzi, M. A. González, A. W. Malick, H. Malinowski, R. Nedich, G. E. Peck, D. M. Pearce, V. Shah, R. F. Shangraw, J. B. Schwartz, and J. Truelove. Scaleup of immediate release oral solid dosage forms. Pharm. Res. 10:313–316 (1993).
J. P. Skelly, G. A. Van Buskirk, D. R. Savello, G. L. Amidon, H. M. Arbit, S. Dighe, M. B. Fawzi, M. A. González, A. W. Malick, H. Malinowski, R. Nedich, D. M. Pearce, G. E. Peck, J. B. Schwartz, V. P. Shah, R. F. Shangraw, and J. Truelove. Scale-up of immediate release oral solid dosage forms. Eur. J. Pharm. Biopharm. 39 (1):40–43 (1993).
J. P. Skelly, W. H. Barr, L. Z. Benet, J. T. Doluisio, A. H. Goldberg, G. Levy, D. T. Lowenthal, J. R. Robinson, V. P. Shah, R. J. Temple, and A. Yacobi. Report of the Workshop on Controlled-Release Dosage Forms: Issues and controversies. Pharm. Res. 4 (1) (1987).
J. P. Skelly, G. L. Amidon, H. Barr, L. Z. Benet, J. E. Carter, J. R. Robinson, V. P. Shah, and A. Yacobi. In vitro and in vivo testing and correlation for oral controlled/modified-release dosage forms. Pharm. Res. 7 (9) (1990).
USP Open Conference on Dissolution, Bioavailability and Bioequivalence; Toronto, Ontario, Canada, June 15–18 (1992).
Pharmacopeial Forum, Vol. 19, No. 3, May–June (1993), p. 5366.
V. P. Shah, J. P. Skelly, W. H. Barr, H. Malinowski, and G. Amidon. Scale-up of controlled release products; Preliminary considerations. Pharm. Tech. 16 (5) (1992).
Rights and permissions
About this article
Cite this article
Skelly, J.P., Van Buskirk, G.A., Arbit, H.M. et al. Scaleup of Oral Extended-Release Dosage Forms. Pharm Res 10, 1800–1805 (1993). https://doi.org/10.1023/A:1018946819849
Issue Date:
DOI: https://doi.org/10.1023/A:1018946819849